{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:17:11Z","timestamp":1788185831894,"version":"build-2803163510"},"reference-count":13,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis Farmac\u00e9utica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.waojou.2022.100721","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T14:12:44Z","timestamp":1669471964000},"page":"100721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps"],"prefix":"10.1016","volume":"15","author":[{"given":"Diego","family":"Bagnasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikki Frank","family":"Canevari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Giacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pigatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luigi","family":"Marseglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu Didem","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.waojou.2022.100721_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.rmed.2017.07.013","article-title":"Long-term \"real-life\" safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study","volume":"130","author":"Di Bona","year":"2017","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.waojou.2022.100721_bib2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ad.2016.07.018","article-title":"Omalizumab in the treatment of chronic inducible urticaria","volume":"108","author":"Chicharro","year":"2017","journal-title":"Actas Dermosifiliogr"},{"issue":"9","key":"10.1016\/j.waojou.2022.100721_bib3","doi-asserted-by":"crossref","first-page":"e047344","DOI":"10.1136\/bmjopen-2020-047344","article-title":"Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials","volume":"11","author":"Wu","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.waojou.2022.100721_bib4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/all.13119","article-title":"AllergoOncology - the impact of allergy in oncology: EAACI position paper","volume":"72","author":"Jensen-Jarolim","year":"2017","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.waojou.2022.100721_bib5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.waojou.2022.100721_bib6","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3109\/02770903.2012.668255","article-title":"Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches","volume":"49","author":"Vennera Mdel","year":"2012","journal-title":"J\u00a0Asthma"},{"issue":"1","key":"10.1016\/j.waojou.2022.100721_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12016-020-08794-6","article-title":"Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence","volume":"59","author":"Metz","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10","key":"10.1016\/j.waojou.2022.100721_bib8","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1111\/all.15008","article-title":"Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database","volume":"76","author":"Mota","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.waojou.2022.100721_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13601-020-00335-w","article-title":"AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a position paper of the European academy of allergy and clinical immunology (EAACI)","volume":"10","author":"Ferastraoaru","year":"2020","journal-title":"Clin Transl Allergy"},{"issue":"4","key":"10.1016\/j.waojou.2022.100721_bib10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.waojou.2022.100721_bib11","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/bjd.20941","article-title":"No association between omalizumab use and risk of cancer: a nationwide registry-based cohort study","volume":"186","author":"Ali","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.waojou.2022.100721_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/14712598.2018.1438406","article-title":"Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic\/spontaneous urticaria: a systematic review of 'real-world' evidence","volume":"18","author":"Bernstein","year":"2018","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"10.1016\/j.waojou.2022.100721_bib13","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/cea.13457","article-title":"Influence of prolonged treatment with omalizumab on the development of solid epithelial cancer in patients with atopic asthma and chronic idiopathic urticaria: a systematic review and meta-analysis","volume":"49","author":"Johnston","year":"2019","journal-title":"Clin Exp Allergy"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455122000977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455122000977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:45:53Z","timestamp":1761849953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455122000977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1939455122000977"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2022.100721","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2022.100721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"100721"}}